Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

NCT03012620 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03012620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2017
Completion date
December 14, 2023
Enrollment
334 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, neuroendocrine, central nervous system neoplasm, neoplasms, germ cell and embryonal, nk/t-cell lymphoma, ovarian neoplasm, sarcoma, thyroid neoplasm